Key Performance Indicators and Performance in Relation to the GRI and ATMI

GRI Logo

Merck reports according to the Global Reporting Initiative (GRI) G3 guidelines on our Corporate Responsibility (CR) website and in our printed CR report. The voluntary GRI G3 guidelines offer a useful framework for transparent reporting about environmental, social and governance performance. Greater transparency on such matters is beneficial to our business because it helps to inform our stakeholders and also enables us to compare performance with peers on relevant metrics. We believe that this will help us focus on continuously improving the things that matter most.

We have self-assessed that we have achieved a reporting level B on the GRI G3 Guidelines, and the GRI has checked our self-assessment.

The table below summarizes where Merck disclosures can be found on the Merck website in relation to the GRI G3 indicators and standard disclosures.

ECONOMIC
	GRI Indicators (Italicized indicators are considered non-core by the GRI and do not require reporting)	Addressed in CR web section or www.merck.com
DMA	Disclosure of management approach for economic performance	Our Economic Impact Valuing Our Employees Our Impact on Local Communities Improving Access to Medicines, Vaccines and Health Care
GRI EC1	Direct economic value generated and distributed, including revenues, operating costs, employee compensation, donations and other community investments, retained earnings, and payments to capital providers and governments	Our Economic Impact Valuing Our Employees Our Impact on Local Communities Improving Access to Medicines, Vaccines and Health Care
GRI EC2	Financial implications and other risks and opportunities for the organization's activities due to climate change	Merck CDP History Page
GRI EC3	Coverage of the organization's defined benefit plan obligations	pp.131-139 of our 2008 Form 10K.
GRI EC4	Significant financial assistance received from government	We do not currently report on this non-core indicator.
GRI EC5	Range of ratios of standard entry level wage compared to local minimum wage at significant locations of operation	We do not currently report on this non-core indicator.
GRI EC6	Policy, practices and proportion of spending on locally-based suppliers at significant locations of operation	Managing Our External Suppliers Fostering Supplier Diversity
GRI EC7	Procedures for local hiring and proportion of senior management hired from the local community at significant locations of operation	Promoting Diversity and Inclusion
GRI EC8	Development and impact of infrastructure investments and services provided primarily for public benefit through commercial, in-kind or probono engagement	Improving Access to Medicines, Vaccines and Health Care Fostering Science Education Our Impact on Local Communities
GRI EC9	Understanding and describing significant indirect economic impacts, including the extent of impacts	Improving Access to Medicines, Vaccines and Health Care Fostering Science Education Our Impact on Local Communities
PRODUCT
DMA	Disclosure of management approach for product performance	Ensuring Confidence in the Safety and Quality of Our Products Product Stewardship
GRI PR1	Life cycle stages in which health and safety impacts of products and services are assessed for improvement, and percentage of significant products and services categories subject to such procedures	Ensuring Confidence in the Safety and Quality of Our Products Product Stewardship
GRI PR2	Total number of incidents of non-compliance with regulations and voluntary codes concerning health and safety impacts of products and services, by type of outcomes	We do not currently report on this non-core indicator.
GRI PR3	Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirements	Ensuring Confidence in the Safety and Quality of Our Products Clinical Trial Registration and Disclosure of Clinical Trials Results Ethical Sales & Marketing Practices
GRI PR4	Total number of incidents of non-compliance with regulations and voluntary codes concerning product and service information, and labeling, by type of outcomes	We do not currently report on this non-core indicator.
GRI PR5	Practices related to customer satisfaction, including results of surveys measuring customer satisfaction	We do not currently report on this non-core indicator.
GRI PR 6	Programs for adherence to laws, standards and voluntary codes related to marketing communications, including advertising, promotion and sponsorship	Ethical Sales & Marketing Practices
GRI PR7	Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion and sponsorship, by type of outcomes	Ethical Sales & Marketing Practices
GRI PR8	Total number of substantiated complaints regarding breaches of customer privacy and losses of customer data	We do not currently report on this non-core indicator.
GRI PR9	Monetary value of significant fines for non-compliance with laws and regulations concerning the provision and use of products and services	Ethical Sales & Marketing Practices
ENVIRONMENTAL
DMA	Disclosure of management approach for environmental performance	Managing Our Environmental Footprint
GRI EN1	Materials used by weight or volume	Emissions, Effluents & Waste
GRI EN2	Percentage of materials used that are recycled input materials	Emissions, Effluents & Waste
GRI EN3	Direct energy consumption by primary energy source	Energy Use and Climate Change
GRI EN4	Indirect energy consumption by primary energy source	Energy Use and Climate Change
GRI EN5	*Energy saved due to conservation and efficiency improvements*	Energy Use and Climate Change
GRI EN6	Initiatives to provide energy-efficient or renewable energy-based products and services, and reductions in energy requirements as a result of these initiatives	We do not report on this non-core indicator because it is not relevant to pharmaceutical products.
GRI EN7	Initiatives to reduce indirect consumption and reductions achieved	Energy Use and Climate Change
GRI EN8	Total water withdrawal by source	Water Use
GRI EN9	Water sources significantly affected by withdrawal of water	We do not currently report on this non-core indicator.
GRI EN10	Percentage and total volume of water recycled and reused	Water Use
GRI EN11	Location and size of land owned, leased, managed in or adjacent to, protected areas and areas of high biodiversity value outside protected areas	We do not currently report on this core indicator.
GRI EN12	Description of significant activities, products and service on biodiversity in these areas.	We do not currently report on this core indicator. Merck has discontinued bioprospecting.
GRI EN13	Habitats protected or restored	We discuss our habitat projects in Our Impact on Local Communities
GRI EN14	Strategies, current actions and future plans for managing impacts on biodiversity	We do not currently report on this non-core indicator.
GRI EN15	Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction risk	We do not currently report on this non-core indicator.
GRI EN16	Total direct and indirect GHG emissions by weight	Energy Use and Climate Change
GRI EN17	Other relevant indirect GHG emissions by weight	Energy Use and Climate Change
GRI EN18	Initiatives to reduce GHG emissions and reductions achieved	Energy Use and Climate Change
GRI EN19	Emissions of ozone-depleting substances by weight	Emissions, Effluents & Waste
GRI EN20	NOx, SOx and other significant air emissions by type and weight	Emissions, Effluents & Waste
GRI EN21	Total water discharge by quality and destination	Emissions, Effluents & Waste
GRI EN22	Total weight of waste by type and disposal method	Emissions, Effluents & Waste
GRI EN23	Total number and volume of significant spills	Safety and Environmental Compliance & Management
GRI EN24	Weight of transported, imported, exported or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III and VIII, and percentage of transported waste shipped internationally	We do not currently report on this non-core indicator.
GRI EN25	Identity, size, protected status, and biodiversity value of water bodies and related habitats significantly affected by the reporting organization's discharges of water and runoff	We do not currently report on this non-core indicator.
GRI EN26	Initiatives to mitigate environmental impacts of products and services, and extent of impact mitigation	Product Stewardship
GRI EN27	Percentage of products sold and their packaging materials that are reclaimed by category	Our products are consumed when used. Unsold product is reclaimed and destroyed for health security reasons. Packaging is not currently being reclaimed.
GRI EN28	Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulation	Safety and Environmental Compliance & Management
GRI EN29	Significant environmental impacts of transporting products and other goods and materials used for the organization's operations, and transporting members of the workforce	We do not currently report on this non-core indicator.
GRI EN30	Total environmental protection expenditures and investments by type	We do not currently report on this non-core indicator.
LABOR
DMA	Disclosure of management approach for labor-related performance	Valuing Our Employees
GRI LA1	Total workforce by employment type, employment contract and region	We report on total number of employees in: Building a Positive Working Environment
GRI LA2	Total number and rate of employee turnover by age group, gender and region	We report turnover number and rate but do not break this down, in: Building a Positive Working Environment
GRI LA3	Benefits provided to full-time employees that are not provided to temporary or part-time employees, by major operations	We report on benefits provided in: Building a Positive Working Environment
GRI LA4	Percentage of employees covered by collective bargaining agreements	Human Rights of Our Employees
GRI LA5	Minimum notice periods regarding significant operational changes, including whether it is specified in collective agreements	Merck does not have the same minimum notice period in all countries. Local legislation and collective bargaining agreement specifications vary, with notice periods ranging from 4 weeks to 6 months.
GRI LA6	Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs	We report on safety committees and occupational health and safety programs in: Fostering the Health and Safety of Our Employees
GRI LA7	Rates of injury, occupational diseases, lost days and absenteeism, and total number of work-related fatalities per region	Fostering the Health and Safety of Our Employees
GRI LA8	Education, training, counseling, prevention and risk-control programs in place to assist workforce members, their families or community members regarding serious diseases	Fostering the Health of Our Employees
GRI LA9	Health and safety topics covered in formal agreements with trade unions	We do not currently report on this non-core indicator.
GRI LA10	Average hours of training per year per employee per category	We have extensive training programs worldwide but do not track average hours globally. For details see: Conducting Ourselves Ethically and Transparently Safety and Environmental Compliance & Management Researching New Medicines and Vaccines to Address Unmet Needs Building a Positive Working Environment
GRI LA11	Programs for skills management and lifelong learning that support the continued employability of employees and assist them with managing career endings	Partially addressed in: Building a Positive Working Environment
GRI LA12	Percentage of employees receiving regular performance and career development reviews	Building a Positive Working Environment
GRI LA13	Composition of governance bodies and breakdown of employees per category according to gender, age group, minority group membership and other diversity indicators	Promoting Diversity and Inclusion. We report data by gender and minority group.
GRI LA14	Ratio of basic salary of men to women by employee category	We do not currently report on this core indicator.
SOCIAL
DMA	Disclosure of management approach for social performance	Our Economic Impact Valuing Our Employees Our Impact on Local Communities Improving Access to Medicines, Vaccines and Health Care Safety and Environmental Compliance & Management Conducting Ourselves Ethically and Transparently Researching New Medicines and Vaccines to Address Unmet Needs Advocacy and Outreach
GRI SO1	Nature, scope and effectiveness of any programs and practices that assess and manage the impacts of operations on communities, including entering, operating and exiting	Our Impact on Local Communities Managing Our Environmental Footprint Neighbor of Choice
GRI SO2	Percentage and total number of business units analyzed for risks related to corruption	Conducting Ourselves Ethically and Transparently
GRI SO3	Percentage of employees trained in the organization's anti-corruption policies and procedures	Conducting Ourselves Ethically and Transparently
GRI SO4	Actions taken in response to incidents of corruption	Conducting Ourselves Ethically and Transparently Researching New Medicines and Vaccines to Address Unmet Needs
GRI SO5	Public policy positions and participation in public policy development and lobbying	Advocacy and Outreach, with specific positions detailed in all the major sections
GRI SO6	Total value of financial and in-kind contributions to political parties, politicians and related institutions, by country	Advocacy and Outreach
GRI SO7	Total number of legal actions for anti-competitive behavior, anti-trust and monopoly practices, and their outcomes	pp.27-46 of our 2008 Form 10K
GRI SO8	Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with laws and regulations	Safety & Environmental Compliance and Management Conducting Ourselves Ethically and Transparently
HUMAN RIGHTS
DMA	Disclosure of management approach to human rights performance	Promoting and Respecting Human Rights
GRI HR1	Percentage and total number of significant investment agreements that include human rights clauses or that have undergone human rights screening	We report on our screening of external suppliers in: Managing Our External Suppliers
GRI HR2	Percentage of significant suppliers and contractors that have undergone screening on human rights, and actions taken	We report on our screening of external suppliers in: Managing Our External Suppliers
GRI HR3	Total hours of employee training on policies and procedures concerning aspects of human rights that are relevant to operations, including the percentage of employees trained	We report on training about ethical business practices in: Conducting Ourselves Ethically and Transparently
GRI HR4	Total number of incidents of discrimination and actions taken	Merck reports the percentage of substantiated (including alternate findings) allegations to concerns/issues raised in connection with our Code of Conduct through AdviceLine or Office of Ethics/Ombudsman. We do not specifically disclose the number of incidents relating to discrimination. When Merck substantiates allegations of ethical misconduct, it imposes a variety of disciplinary actions on those responsible for the misconduct, such as dismissal from the Company, issuance of final written warning letters and financial penalties. See: Conducting Ourselves Ethically and Transparently
GRI HR5	Operations identified in which the right to exercise freedom of association and collective bargaining may be at significant risk, and actions taken to support these rights	Promoting and Respecting Human Rights
GRI HR6	Operations identified as having significant risk for incidents of child labor, and measures taken to contribute to the elimination of child labor	Promoting and Respecting Human Rights
GRI HR7	Operations identified as having significant risk for incidents of forced or compulsory labor, and measures taken to contribute to the elimination of forced or compulsory labor	Promoting and Respecting Human Rights Managing Our External Suppliers
GRI HR8	Percentage of security personnel trained in the organization's policies and procedures concerning aspects of human rights that are relevant to operations	We do not currently report on this non-core indicator.
GRI HR9	Total number of incidents or violations involving rights of indigenous people, and actions taken	We do not currently report on this non-core indicator.

STRATEGY AND ANALYSIS
Number	GRI Standard Disclosures	Addressed in CR web section or www.merck.com
1.1	Executive management statement	Message from the Chairman
1.2	Description of key impacts, risks and opportunities	Our Economic Impact Researching New Medicines and Vaccines to Address Unmet Needs Improving Access to Medicines, Vaccines and Health Care Ensuring Confidence in the Safety and Quality of Our Products Conducting Ourselves Ethically and Transparently Managing Our Environmental Footprint Fostering the Health and Safety of Our Employees Advocacy and Outreach Our Impact on Local Communities
ORGANIZATION PROFILE
2.1	Name of organization	Merck & Co., Inc.
2.2	Primary brands, products, and/or services	About Merck Our Economic Impact pp. 6-8 of the 2008 Form 10K
2.3	Operational structure of the organization	Corporate Governance
2.4	Location of organization's headquarters	Whitehouse Station, New Jersey, U.S.A.
2.5	Number of countries where the organization operates	Our Economic Impact
2.6	Nature of ownership and legal form	Public company listed on NYSE under the symbol MRK
2.7	Markets served	Our Economic Impact
2.8	Scale of reporting organization	Our Economic Impact
2.9	Significant changes during the reporting period regarding size, structure or ownership	Merck & Schering Plough to Merge Restructuring Program
2.10	Awards received in the reporting period	Awards, Recognition and Benchmarking
REPORT PARAMETERS
3.1	Reporting period	Frequently Asked Questions
3.2	Date of most recent previous report	Corporate Responsibility 2008 Report, Advancing the Dialogue Toward a Healthier Future
3.3	Reporting cycle	Frequently Asked Questions
3.4	Contact points for questions regarding the report and its contents	Contact Corporate Responsibility
3.5	Process for defining report content	Materiality Assessment Process
3.6	Boundary of the report	Materiality Assessment Process
3.7	State any specific limitations on the scope or boundary of the report	Materiality Assessment Process
3.8	Basis for reporting on joint ventures, subsidiaries, leased facilities, outsourced operations, and other entities	pp. 93-97 of the 2008 Form 10K
3.9	Data measurement techniques and the bases of calculations	Managing Our Environmental Footprint The Safety of Our Employees
3.10	Explanation of the effects of any restatement of information provided in earlier reports	Managing Our Environmental Footprint The Safety of Our Employees
3.11	Significant changes from previous reporting periods	CR Governance and Performance Management
3.12	Table identifying the location of standard disclosures in the report	This table
3.13	Policy and current practice with regard to seeking external assurance for the report	External Stakeholder Review of Reporting Approach
GOVERNANCE
4.1	Governance structure of the organization	Corporate Governance
4.2	Indicate whether the Chair of the highest governance body is also an executive officer	Corporate Governance
4.3	Members of the highest governance body that are independent and/or non-executive members	Corporate Governance
4.4	Mechanisms for shareholders and employees to provide recommendations or direction to the highest governance body	Annual Shareholder meetings, Proxy voting, Communicating and Engaging With Our Employees
4.5	Linkage between compensation and the organization's performance	Building a Positive Working Environment Corporate Governance pp. 22-41 of our 2008 Proxy Statement, with regard to executive compensation
4.6	Processes in place for the highest governance body to ensure conflicts of interest are resolved	Conducting Ourselves Ethically and Transparently
4.7	Process for determining the qualifications and expertise of the members of the highest governance body for guiding the organization's strategy on economic, environmental and social performance	Corporate Governance
4.8	Internally developed statement of mission or values, codes of conduct, and principles relevant to economic, environmental and social performance and the status of their implementation	Conducting Ourselves Ethically and Transparently Corporate Governance Safety and Environmental Compliance & Management
4.9	Procedures of the highest governance body for overseeing the organization's identification and management of economic, environmental and social performance	Corporate Governance Our CR Approach Conducting Ourselves Ethically and Transparently Safety and Environmental Compliance & Management
4.10	Process for evaluating the highest governance body's own performance, particularly with respect to economic, environmental and social performance	Policies of the Board Safety & Environmental Compliance and Management
4.11	Explanation of whether and how the precautionary approach or principles is addressed by the organization	Product Stewardship
4.12	Externally developed economic, environmental and social charters, principles or other initiatives to which the organization subscribes or which it endorses	Our Economic Impact Researching New Medicines and Vaccines to Address Unmet Needs Improving Access to Medicines, Vaccines and Health Care Ensuring Confidence in the Safety and Quality of Our Products Conducting Ourselves Ethically and Transparently Managing Our Environmental Footprint Advocacy and Outreach Managing Our External Suppliers
4.13	Significant memberships in organizations	Advocacy and Outreach, also mentioned in all major sections
4.14	List of stakeholder groups engaged by the organization	Engaging With Our Stakeholders
4.15	Basis for identification and selection of stakeholders with whom organization engages	Engaging With Our Stakeholders Merck and Public Private Partnerships
4.16	Approaches to stakeholder engagement, including frequency of engagement by type and by stakeholder group	Engaging With Our Stakeholders Merck and Public Private Partnerships Our Impact on Local Communities
4.17	Key topics and concerns that have been raised through stakeholder engagement, and how the organization has responded to those key topics and concerns, including through its reporting	Engaging With Our Stakeholders External Stakeholder Review of Reporting Approach

The content on this page was last modified on September 15, 2009.

Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.

Summary of Global ReportingInitiative Indicators

Summary of Global Reporting
Initiative Indicators